Donald A Picker

US Patent:

20210322372, Oct 21, 2021

Filed:

Apr 12, 2021

Appl. No.:

17/228054

Inventors:

- New York NY, US
Jason STEIN - New York NY, US
Donald PICKER - Jersey City NJ, US

Assignee:

Cortice Biosciences, Inc. - New York NY

International Classification:

A61K 31/357
A61P 25/28

Abstract:

The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.

US Patent:

20170281592, Oct 5, 2017

Filed:

Jun 15, 2017

Appl. No.:

15/624263

Inventors:

- New York NY, US
Jason STEIN - New York NY, US
Donald PICKER - Jersey City NJ, US

Assignee:

Cortice Biosciences, Inc. - New York NY

International Classification:

A61K 31/357

Abstract:

The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula (1a); Formula (1a); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of (1a) and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologically active agents.

US Patent:

20160175279, Jun 23, 2016

Filed:

Jul 2, 2014

Appl. No.:

14/902190

Inventors:

- New York NY, US
Jason STEIN - New York NY, US
Donald PICKER - Jersey City NJ, US

Assignee:

Cortice Biosciences, Inc. - New York NY

International Classification:

A61K 31/357

Abstract:

The present disclosure is directed, at least in part, to disease-modifying treatments for neurodegenerative disorders. In one embodiment, a method of delaying worsening of one or more symptoms and/or progression of a neurodegenerative disorder is provided. In one embodiment, a method of treating or ameliorating one or more symptoms of a neurodegenerative disorder is provided. In one embodiment, the methods of the present invention comprise administering to a subject in need thereof, a compound having the structure of Formula ():Formula (); and/or a pharmaceutically acceptable salt thereof. In one embodiment, the the compound of () and/or a pharmaceutically acceptable salt thereof is administered in combination with one or more pharmacologic ally active agents.